IN2014CN02949A - - Google Patents
Info
- Publication number
- IN2014CN02949A IN2014CN02949A IN2949CHN2014A IN2014CN02949A IN 2014CN02949 A IN2014CN02949 A IN 2014CN02949A IN 2949CHN2014 A IN2949CHN2014 A IN 2949CHN2014A IN 2014CN02949 A IN2014CN02949 A IN 2014CN02949A
- Authority
- IN
- India
- Prior art keywords
- diabetes
- pain
- fibromyalgia
- insulin resistance
- type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011228822 | 2011-10-18 | ||
| PCT/JP2012/076771 WO2013058258A1 (ja) | 2011-10-18 | 2012-10-17 | 二環式ヘテロ環化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02949A true IN2014CN02949A (https=) | 2015-07-03 |
Family
ID=48140904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2949CHN2014 IN2014CN02949A (https=) | 2011-10-18 | 2012-10-17 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9266840B2 (https=) |
| EP (1) | EP2772484B1 (https=) |
| JP (1) | JP6020459B2 (https=) |
| KR (1) | KR101987514B1 (https=) |
| CN (1) | CN103917524B (https=) |
| AR (1) | AR088378A1 (https=) |
| AU (1) | AU2012327076B2 (https=) |
| BR (1) | BR112014009524A2 (https=) |
| CA (1) | CA2851589C (https=) |
| CY (1) | CY1119181T1 (https=) |
| DK (1) | DK2772484T3 (https=) |
| EA (1) | EA024846B1 (https=) |
| ES (1) | ES2641258T3 (https=) |
| HR (1) | HRP20171125T1 (https=) |
| IL (1) | IL232061A (https=) |
| IN (1) | IN2014CN02949A (https=) |
| LT (1) | LT2772484T (https=) |
| ME (1) | ME02733B (https=) |
| MX (1) | MX344014B (https=) |
| PH (1) | PH12014500820A1 (https=) |
| PL (1) | PL2772484T3 (https=) |
| PT (1) | PT2772484T (https=) |
| RS (1) | RS56288B1 (https=) |
| SI (1) | SI2772484T1 (https=) |
| TW (1) | TWI545113B (https=) |
| UA (1) | UA112327C2 (https=) |
| WO (1) | WO2013058258A1 (https=) |
| ZA (1) | ZA201403513B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2844259A4 (en) | 2012-04-30 | 2015-11-11 | Anderson Gaweco | MMR MODULATORS AND USES THEREOF |
| US9045477B2 (en) | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US9776996B2 (en) * | 2013-03-15 | 2017-10-03 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| CA2990583A1 (en) * | 2015-06-22 | 2016-12-29 | Sumitomo Dainippon Pharma Co., Ltd. | 1,4-disubstituted imidazole derivative |
| WO2017096148A1 (en) * | 2015-12-03 | 2017-06-08 | Katz Robert S | Methods and systems for diagnosing and treating fibromyalgia |
| CN108129430A (zh) * | 2016-11-30 | 2018-06-08 | 重庆圣华曦药业股份有限公司 | 一种立他司特中间体的合成方法 |
| CN115925692A (zh) * | 2022-11-28 | 2023-04-07 | 浙江理工大学 | 一种三氟甲基取代的烯胺化合物的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0258095B1 (fr) * | 1986-08-12 | 1991-06-12 | Roussel-Uclaf | Nouveaux dérivés de la décahydroquinoléine, leur procédé de préparation et les nouveaux intermédiaires obtenus, leur application à titre de médicaments et les compositions pharmaceutiques les renfermant |
| GB8907865D0 (en) * | 1989-04-07 | 1989-05-24 | Wyeth John & Brother Ltd | Tetrahydroquinoline derivatives |
| US5194439A (en) * | 1990-04-06 | 1993-03-16 | John Wyeth & Brother Limited | N-(2,3-dihydro-1,4-benzodioxinyl)-N-substituted aminopyrido-fused cycloalkanes |
| DE69602248T4 (de) * | 1995-07-20 | 2000-10-26 | Toray Industries, Inc. | 4a-aryldecahydroisochinolin-verbindungen und ihre medizinische verwendungen |
| JP2003527395A (ja) | 2000-03-17 | 2003-09-16 | ノボ ノルディスク アクティーゼルスカブ | ヒスタミンｈ３受容体リガンドとしての縮環イミダゾール |
| EP1487796A4 (en) | 2002-03-28 | 2005-11-16 | Neurogen Corp | SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR |
| ATE482747T1 (de) | 2003-04-11 | 2010-10-15 | High Point Pharmaceuticals Llc | Neue amide derivate und deren pharmazeutische verwendungen |
| EP1675844A1 (en) * | 2003-10-23 | 2006-07-05 | Sterix Limited | Phenyl carboxamide and sulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase |
| JPWO2006104280A1 (ja) * | 2005-03-31 | 2008-09-11 | 武田薬品工業株式会社 | 糖尿病の予防・治療剤 |
| JP5023054B2 (ja) | 2005-03-31 | 2012-09-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗バクテリア剤としての二環式ピラゾール化合物 |
| WO2007050124A1 (en) | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
| TW200716576A (en) | 2005-06-07 | 2007-05-01 | Shionogi & Co | Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| US7605289B2 (en) | 2005-06-17 | 2009-10-20 | Amgen, Inc. | Benzamide derivatives and uses related thereto |
| WO2007069773A1 (en) | 2005-12-15 | 2007-06-21 | Shionogi & Co., Ltd. | A pharmaceutical composition comprising an amide derivative |
| AU2007240450B2 (en) * | 2006-04-21 | 2011-12-22 | Eli Lilly And Company | Cyclohexylimidazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| JP5161869B2 (ja) * | 2006-04-21 | 2013-03-13 | イーライ リリー アンド カンパニー | １１−β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤としての、シクロヘキシルピラゾール−ラクタム誘導体 |
| DK2021337T3 (da) | 2006-04-25 | 2010-03-29 | Lilly Co Eli | Inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1 |
| ATE476418T1 (de) | 2006-06-08 | 2010-08-15 | Amgen Inc | Benzamidderivate und assoziierte verwendungen |
| TW200808695A (en) | 2006-06-08 | 2008-02-16 | Amgen Inc | Benzamide derivatives and uses related thereto |
| WO2008065500A2 (en) * | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| CA2673586A1 (en) | 2006-12-26 | 2008-07-24 | Amgen Inc. | N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases |
| WO2011090738A2 (en) | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| UA112418C2 (uk) | 2010-09-07 | 2016-09-12 | Астеллас Фарма Інк. | Терапевтичний болезаспокійливий засіб |
| WO2012080729A2 (en) | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
-
2012
- 2012-10-17 KR KR1020147012520A patent/KR101987514B1/ko active Active
- 2012-10-17 TW TW101138258A patent/TWI545113B/zh active
- 2012-10-17 WO PCT/JP2012/076771 patent/WO2013058258A1/ja not_active Ceased
- 2012-10-17 PT PT128409901T patent/PT2772484T/pt unknown
- 2012-10-17 SI SI201231017T patent/SI2772484T1/sl unknown
- 2012-10-17 ME MEP-2017-145A patent/ME02733B/me unknown
- 2012-10-17 PH PH1/2014/500820A patent/PH12014500820A1/en unknown
- 2012-10-17 DK DK12840990.1T patent/DK2772484T3/en active
- 2012-10-17 EP EP12840990.1A patent/EP2772484B1/en active Active
- 2012-10-17 UA UAA201405224A patent/UA112327C2/uk unknown
- 2012-10-17 LT LTEP12840990.1T patent/LT2772484T/lt unknown
- 2012-10-17 US US14/351,965 patent/US9266840B2/en active Active
- 2012-10-17 RS RS20170733A patent/RS56288B1/sr unknown
- 2012-10-17 IN IN2949CHN2014 patent/IN2014CN02949A/en unknown
- 2012-10-17 HR HRP20171125TT patent/HRP20171125T1/hr unknown
- 2012-10-17 AU AU2012327076A patent/AU2012327076B2/en active Active
- 2012-10-17 MX MX2014004701A patent/MX344014B/es active IP Right Grant
- 2012-10-17 EA EA201490811A patent/EA024846B1/ru not_active IP Right Cessation
- 2012-10-17 CN CN201280051414.6A patent/CN103917524B/zh active Active
- 2012-10-17 PL PL12840990T patent/PL2772484T3/pl unknown
- 2012-10-17 BR BR112014009524A patent/BR112014009524A2/pt not_active Application Discontinuation
- 2012-10-17 CA CA2851589A patent/CA2851589C/en active Active
- 2012-10-17 ES ES12840990.1T patent/ES2641258T3/es active Active
- 2012-10-17 JP JP2013539653A patent/JP6020459B2/ja active Active
- 2012-10-18 AR ARP120103883A patent/AR088378A1/es active IP Right Grant
-
2014
- 2014-04-10 IL IL232061A patent/IL232061A/en active IP Right Grant
- 2014-05-15 ZA ZA2014/03513A patent/ZA201403513B/en unknown
-
2017
- 2017-07-31 CY CY20171100826T patent/CY1119181T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN02949A (https=) | ||
| MX2009011276A (es) | Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad. | |
| PH12016502103B1 (en) | Novel disubstituted 1,2, 4-triazine compound | |
| MX2013010552A (es) | Compuestos de guanidina. | |
| PH12013502156A1 (en) | 1,3-oxazines as bace1 and/or bace2 inhibitors | |
| EA201391752A1 (ru) | Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2 | |
| EA201390198A1 (ru) | Гетероциклическое соединение | |
| WO2012117000A8 (en) | 3-amino-pyridines as gpbar1 agonists | |
| MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| MX2018001204A (es) | Metodo para preparar derivados de acido 3-(2-anilino-1-ciclohexil- 1h-bencimidazol-5-il)propanoico sustituido. | |
| GEP20166481B (en) | (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors | |
| PH12019500394A1 (en) | Bicyclic nitrogenated heterocyclic compound | |
| PH12016502130B1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| MX2016012318A (es) | Compuesto amidico. | |
| WO2014188329A3 (en) | Transdermal extended dosing of pramipexole for neurological disorders | |
| WO2011159137A3 (ko) | 신규한 티오우레아 또는 우레아 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물 | |
| IN2014MN02622A (https=) | ||
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| MX379373B (es) | Derivado de sulfonamida heterocíclico y medicina que contiene el mismo. | |
| PH12015502341A1 (en) | Heterocyclic acetic acid amide compound | |
| MX2018014165A (es) | Compuestos heterociclicos utiles como agentes antibacterianos y metodo de produccion. | |
| WO2018062876A3 (ko) | 통증이 경감되는 골관절염 치료용 키트 | |
| NZ707832A (en) | 2-pyridone compound | |
| MX2013011561A (es) | Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. |